Angiotensin-Converting Enzyme Inhibitors (ACE) in Congestive Heart Failure
Osamu Fukuyama
Abstract
Osamu Fukuyama
Abstract
To the Editor — Deedwania1presented an excellent review on the use of ACE inhibitors in congestive heart failure, but I do not believe there is enough data to support his conclusion that ... a short-acting ACE inhibitor such as captopril may be preferred for the treatment of selected patients with CHF [congestive heart failure] to minimize these risks. Although he had mentioned the interim report of the multicenter lisinoprilcaptopril congestive heart failure study group,2his article omitted their final report3that showed that lisinopril was superior in improving ejection fraction, functional capacity, and quality of life and that it produced fewer serious adverse experiences compared with captopril. At present, the data are inconclusive regarding the superiority of one ACE inhibitor over other agents, and absolutely agree with Jessup's opinion that ... unfortunately, until more research is accomplished, the choice of an ACE inhibitor for the patient with heart
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
To the Editor — Deedwania1presented an excellent review on the use of ACE inhibitors in congestive heart failure, but I do not believe there is enough data to support his conclusion that ... a short-acting ACE inhibitor such as captopril may be preferred for the treatment of selected patients with CHF [congestive heart failure] to minimize these risks. Although he had mentioned the interim report of the multicenter lisinoprilcaptopril congestive heart failure study group,2his article omitted their final report3that showed that lisinopril was superior in improving ejection fraction, functional capacity, and quality of life and that it produced fewer serious adverse experiences compared with captopril. At present, the data are inconclusive regarding the superiority of one ACE inhibitor over other agents, and absolutely agree with Jessup's opinion that ... unfortunately, until more research is accomplished, the choice of an ACE inhibitor for the patient with heart
Key concepts: Heart failure, Angiotensin-converting enzyme, Cardiology, Internal medicine, Medicine, ACE inhibitor, Enzyme, Chemistry